Jim Cramer Questions Agilent Technologies' Value, Citing Limited Growth Outlook

Jim Cramer, host of CNBC’s 'Mad Money,' voiced caution regarding Agilent Technologies (AGN), telling viewers he doesn’t believe the stock is necessary for most portfolios. The comment, made during a recent segment, underscored his broader skepticism about mid-cap industrial and healthcare technology equities amid uncertain macroeconomic conditions. AGN, which reported $3.4 billion in revenue for fiscal year 2025, has seen its stock rise 12% year-to-date as of March 2026, outpacing the broader S&P 500’s 7% gain. However, Cramer highlighted that the company’s forward P/E ratio of 24.6 and modest 4.1% expected earnings growth over the next 12 months make it less compelling relative to faster-growing peers in the semiconductor and biotech segments. The analyst also noted that Agilent operates in a capital-intensive, low-margin environment where innovation cycles are long and customer demand—particularly in life sciences research—is sensitive to government funding and R&D budget fluctuations. With the VIX index at 18.3 as of March 11, 2026, reflecting elevated market anxiety, Cramer advised caution on stocks with limited upside catalysts. Investors in AGN, which trades at $224.70 per share on the NYSE, may face short-term volatility, especially if interest rates remain elevated and corporate spending slows. The broader health tech sector, including peers like Thermo Fisher Scientific (TMO) and Danaher (DHR), has also faced pressure, with CL=F (crude oil) trading at $89.40 per barrel, indicating ongoing macroeconomic uncertainty. Cramer’s remarks are not a sell signal but a reminder to assess positioning carefully. He recommended focusing on companies with clearer earnings momentum and scalability, even if they carry higher valuation multiples.